Evidence map›Paper›PMID 40330453›Full record

ArticleContemporary oncology (Poznan, Poland)2025

Age and smoking intensity in non-small cell lung cancer patients with the anaplastic lymphoma kinase fusion gene.

Yosuke Maezawa, Manato Taguchi, Takeshi Kawakami, Toshihide Inui, Shinichiro Okauchi, Takeshi Numata, Toshihiro Shiozawa, Kunihiko Miyazaki, Ryota Nakamura, Kesato Iguchi and 4 more

Abstract read
In one paragraph

Article in Contemporary oncology (Poznan, Poland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Living WithJTO clinical and research reports · 2026
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yosuke MaezawaMito Medical Centre, University of Tsukuba-Mito Kyodo General Hospital, Mito Japan.
Manato TaguchiKobari General Hospital, Noda, Japan.
Takeshi KawakamiKobari General Hospital, Noda, Japan.
Toshihide InuiUniversity of Tsukuba Hospital, Tsukuba, Japan.
Shinichiro OkauchiMito Medical Centre, University of Tsukuba-Mito Kyodo General Hospital, Mito Japan.
Takeshi NumataNational Hospital Organization Mito Medical Centre, Mito, Japan.
Toshihiro ShiozawaUniversity of Tsukuba Hospital, Tsukuba, Japan.
Kunihiko MiyazakiRyugasaki Saiseikai Hospital, Ryugasaki, Japan.
Ryota NakamuraNational Hospital Organization Mito Medical Centre, Mito, Japan.
Kesato IguchiMito Medical Centre, University of Tsukuba-Mito Kyodo General Hospital, Mito Japan.
Takeo EndoNational Hospital Organization Mito Medical Centre, Mito, Japan.
Tohru SakamotoTsukuba Memorial Hospital, Tsukuba, Japan.
Hiroaki SatohMito Medical Centre, University of Tsukuba-Mito Kyodo General Hospital, Mito Japan.
Nobuyuki HizawaUniversity of Tsukuba Hospital, Tsukuba, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: It is widely accepted that anaplastic lymphoma kinase (ALK) fusion gene-positive non-small cell lung cancer (NSCLC) patients are more likely to be in their 50s, female, and non-smoking. This seems to be due to the background of patients involved in clinical trials of ALK-tyrosine kinase inhibitors. However, in daily clinical practice, it is not uncommon to encounter elderly ALK-positive NSCLC patients with a smoking history. In light of this background, we conducted a survey to clarify the clinical backgrounds of ALK-positive patients with NSCLC, particularly regarding age and smoking. Material and methods: A retrospective medical chart survey of patients with ALK-positive NSCLC diagnosed in 2012 to 2024 in our six institutes was conducted. Results: During the study period, 140 pa-- tients were diagnosed with ALK-positive NSCLC, of which 90 (64.3%) were women. The median age of all 140 pa-- tients was 63 years (range, 26-84 years). Among these 140 patients, 38.6% had a history of smoking. There was a significant difference in the distribution of smokers by sex and age. Conclusions: Even among NSCLC patients who are elderly or have a history of smoking, there may be some who miss out on the best possible treatment by exclusion from ALK testing. Discussions considering the efficiency and cost of testing are needed, and it is essential to collect and reanalyse as much information as possible about the clinical characteristics of ALK-positive NSCLC patients.

Indexed as

ageALKanaplastic lymphoma kinase fusion genedriver genegendernon-small cell lung cancersmoking

Identifiers

PMID40330453
PMCPMC12051883

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.